Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults

Journal of Hepatology

Volumn 26, Issue 2, 1997, Pages 260-264

  Chen, X Q ^b   Bulbul M ^b   De Gast, G C ^b   Van Loon, A M ^b   Nalin, D R ^a   Van Hattum, J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

adults; hepatitis; immunogenicity; vaccine

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; VACCINATION; VOLUNTEER;

EID: 0342275221     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80039-6     Document Type: Article

References (24)

1. Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum globulin. J Infect Dis. 156:1987;56-63.
2. Sheretz RJ, Russel BA, Reuman PD. Transmission of hepatitis A by transfusion of blood products. Arch Int Med. 144:1984;1579-1584.
3. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993 - June 1994. MMWR. 43:1994;506-509.
4. Provost PJ, Hilleman MR. Propagation of human hepatitis A in cell culture in vitro. Proc Soc Exp Biol Med. 160:1979;213-221.
5. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, Ryan J, Provost P, Nalin D. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 327:1992;453-457.
6. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozit CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB, Boslego JW. Protection against hepatitis A by an inactivated vaccine. JAMA. 271:1994;1328-1334.
7. Nalin D, Brown L, Kuter B, Patterson C, McGuire B, Werzberger A, Santosham M, Block S, Reisinger K, Watson B, Starr S, Pickering L, Lewis J, Miller W, Calandra G, Blatter M. Inactivated hepatitis A vaccine in childhood: implications for disease control. Vaccine. 11:1993;15-17. (Suppl.1).
8. Shouval D, Ashur Y, Adler R, Lewis JA, Miller W, Kuter B, Brown L, Nalin DR. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol. 18:1993;32-37. (Suppl.2).
9. Tilzey AJ, Palmer S, Barrow S, Perry KR, Tyrrell H, Safary A, Banatvala JE. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. Br Med J. 304:1992;1272-1276.
10. Ellerbeck EF, Lewis JA, Nalin D, Gershman K, Miller WJ, Armstrong ME, Davide JP, Rhoad AE, McGuire B, Calandra G, Provost PJ, Midthun K. Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. Vaccine. 10:1992;668-672.
11. Provost PJ, Bishop RP, Gerety RJ, Hillema MR, McAleer WJ, Scolnick EM, Stevens CE. New finding in live, attenuated hepatitis A vaccine development. J Med Virol. 20:1986;165-175.
12. Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA. Development of the formalin-inactivated hepatitis A vaccine, VAQTA™ from the live attenuated virus strain CR326F. J Hepatol. 18:1993;20-26. (Suppl.2).
13. André FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an activated hepatitis A vaccine: rationale and summary of findings. Vaccine. 10:1992;160-168. (Suppl.1).
14. Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. J Med Virol. 24:1988;377-384.
15. Wismans PJ, van Hattum J, de Gast GC, Endeman HJ, Poel J, Stolk B, Maikoe T, Mudde GC. The spot-Elisa assay: A sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin Exp Immunol. 78:1989;75-78.
16. Wagner G, Lavanchy D, Darioli R, Pécoud A, Brulein V, Safary A, Frei PC. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine. 11:1993;1027-1032.
17. Desmyter J, Colaert J, De Groote G, Reynders M, Reerink-Brongers EE, Lelie PN, Dees PJ, Reesink HW. Efficacy of heat-inactivated hepatitis B vaccine in hemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet. ii:1983;1323-1328.
18. Morris CA, Oliver PR, Reynolds F, Selkon JB. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. Epidemiol Inf. 103:1989;387-394.
19. Cook JM, Gualde N, Hassel L, Mounier M, Michel JP, Denis F, Ratinaud H. Alteration in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol. 109:1987;89-96.
20. Carlsson RM, Claesson BA, Iwarson SA. Dose response study of inactivated hepatitis A virus vaccine. J Hepatol. 18:1993;41-45. (Suppl 2).
21. van Hattum J, Maikoe T, Poel J, de Gast GC. In vitro anti-HBs production of individual B cells of responders to hepatitis B vaccine who subsequently lost antibody. Hollinger BF, Lemon SM, Margolis HS. Viral Hepatitis and Liver Disease, Proc 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. 774-776:1991;Williams & Wilkins, Baltimore.
22. Midthun K, Ellerbeck E, Gershman K, Calandra G, Krah D, McCaughtry M, Nalin D, Provost P. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis. 163:1991;735-739.
23. Mao JS, Dong DX, Zhang HY, Chen NL, Zhang XY, Huang HY, Xie RY, Zhou TJ, Wan ZJ, Wang YZ, Hu ZH, Cao YY, Li HM, Chu CM. Primary study of attenuated live hepatitis A vaccine (H2 Strain) in humans. J Infect Dis. 159:1989;621-624.
24. Provost PJ, Hughes JV, Miller WJ, Giesa PA, Banker FS, Emini EA. An activated hepatitis A viral vaccine of cell culture origin. J Med Virol. 19:1986;23-31.